Drug-Induced Cognitive Impairment and Dementia

被引:0
|
作者
O. D. Ostroumova [1 ]
T. M. Ostroumova [2 ]
A. I. Kochetkov [1 ]
A. E. Vorobyova [1 ]
A. A. Gadzhibekov [3 ]
D. A. Sychev [1 ]
机构
[1] Russian Medical Academy of Continuing Professional Education,
[2] Russian Ministry of Health,undefined
[3] Sechenov First Moscow State Medical University (Sechenov University),undefined
[4] Russian Ministry of Health,undefined
[5] Central Clinical Hospital “RZD-Medicine”,undefined
关键词
cognitive impairment; dementia; drug-induced diseases; drug-induced cognitive impairment/dementia; adverse drug reactions;
D O I
10.1007/s11055-024-01686-8
中图分类号
学科分类号
摘要
Causes of the development or aggravation of cognitive impairment (CI) may include the use of a number of drugs, including non-steroidal anti-inflammatory drugs, antiarrhythmics, antidepressants, glucocorticosteroids, antitumor drugs, and various others. The adverse effects of drugs on cognitive functions are mediated by many pathophysiological mechanisms: disruption of hormonal regulation, decreased neuronal excitability, increased γ-aminobutyric acid receptor activity, decreased cerebral blood flow, and atrophic changes in the brain; many mechanisms remain to be established definitively. Risk factors for the development of drug-induced (DI) CI are old age, childhood, brain damage, chronic diseases, and genetic factors, along with the presence of early CI in the patient, polypharmacy, dose and duration of drug use, acute infectious diseases, metabolic disorders, dehydration, acute urinary retention, and others. The diagnosis and differential diagnosis of DI CI requires a connection between the start of taking the proposed drug inductor and CI to be established. The first step in the treatment of DI CI is discontinuation of the inducing drug or reduction in the dosage; when discontinuation of the drug is not possible and there is no replacement, special slow-release dosage forms can be considered. The main measures to prevent DI CI include the use of drugs with the lowest risk of their development, assessment of drug interactions, and the use of modern scales to assess the risk of developing this side effect (such as the anticholinergic burden scale).
引用
收藏
页码:870 / 877
页数:7
相关论文
共 50 条
  • [31] Tools for clinical pharmacists to identify medications that can cause drug-induced cognitive impairment: A systematic review
    Stanton, Jacob
    Gionfriddo, Michael R.
    Rattinger, Gail B.
    Fang, Yuan
    Lussier, Mia E.
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2024, 7 (12): : 1207 - 1227
  • [32] Cellular messenger molecules mediating addictive drug-induced cognitive impairment: cannabinoids, ketamine, methamphetamine, and cocaine
    Sim, Hye In
    Kim, Dae Hyun
    Kim, Mikyung
    FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 8 (01)
  • [33] Identification of pharmacological targets involved in drug-induced thermoregulation impairment
    Roquigny, Julia
    Delaunois, Annie
    Schramm, Carolin
    Valentin, Jean-Pierre
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2021, 111
  • [34] Drug-Induced Sleep-Disordered Breathing and Ventilatory Impairment
    Grote, Ludger
    SLEEP MEDICINE CLINICS, 2018, 13 (02) : 161 - +
  • [35] The zebrafish as an invivo model of drug-induced hearing and vestibular impairment
    Buck, Lauren
    Winter, Matthew J.
    Redfern, William S.
    Whitfield, Tanya T.
    MECHANISMS OF DEVELOPMENT, 2009, 126 : S330 - S330
  • [36] Inappropriate Drug Use in People with Cognitive Impairment and Dementia: A Systematic Review
    Johnell, Kristina
    CURRENT CLINICAL PHARMACOLOGY, 2015, 10 (03): : 178 - 184
  • [37] Diagnosis of Dementia and Cognitive Impairment
    Larner, Andrew J.
    DIAGNOSTICS, 2019, 9 (04)
  • [38] Cognitive impairment and vascular dementia
    Munoz-Perez, Maria Jose
    Espinosa-Villasenor, Daniela
    REVISTA MEXICANA DE NEUROCIENCIA, 2016, 17 (06): : 85 - 96
  • [39] Vascular cognitive impairment in dementia
    Etherton-Beer, Christopher D.
    MATURITAS, 2014, 79 (02) : 220 - 226
  • [40] Falls in cognitive impairment and dementia
    Shaw, FE
    CLINICS IN GERIATRIC MEDICINE, 2002, 18 (02) : 159 - +